Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

n and our financial performance.

Our actual results may vary depending on a variety of factors, including:

  • the development of competitive generic versions of oral Vancocin;
  • our ability to successfully commercialize Cinryze;
  • our ability to receive regulatory approval for the use of Cinryze for the acute treatment of HAE;
  • the availability of third party payer reimbursement for Cinryze patients;
  • our ability to develop a clinical development program for maribavir;
  • approval of products which are currently marketed for other indications by other companies or new pharmaceuticals and technological advances to treat the conditions addressed by Vancocin or Cinryze;
  • fluctuations in wholesaler order patterns and inventory levels;
  • manufacturing, supply or distribution interruptions, including but not limited to our ability to acquire adequate supplies of Vancocin and Cinryze to meet demand for the product;
  • changes in prescribing or procedural practices of physicians, including off-label prescribing of products competitive with Vancocin and Cinryze;
  • the timing of regulatory submissions and approvals;
  • actions by the FDA, EMEA and the Internal Revenue Service or other government regulatory agencies;
  • decreases in the rate of infections for which Vancocin is prescribed or decreases in the sensitivity of the relevant bacteria to Vancocin;
  • an impairment of our intangible assets if our market capitalization remains less than our book value;
  • the timing and results of anticipated events in our clinical development programs; and
  • the timing and nature of potential business development activities related to our efforts to expand our current portfolio through in-licensing or other means of acquiring produ
    '/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... 2015 Six startups from Russia ... 4-17 as part of the U.S.-Russia Innovation Corridor ... of biotechnology startups to participate in the program ... and the University of Maryland (UMD) signed a ... respective universities in the biomedical industry in 2013. ...
(Date:4/23/2015)... , April 23, 2015 WuXi PharmaTech (Cayman) ... capability and technology platform company serving the pharmaceutical, biotechnology ... China and the United States ... results for the first quarter of 2015 after the ... 2015 (which will be Thursday morning, May 14, 2015 ...
(Date:4/23/2015)... 2015  Cryoport, Inc. (OTCBB: CYRX) ("Company"), the ... the life sciences industry, today announced that the ... within the animal husbandry market by signing a ... the shipment of equine semen for artificial insemination ... Animal husbandry is a multi-billion dollar ...
(Date:4/23/2015)... -- Prospects for Leading Companies in OTC, ...   We predict the global healthcare packaging ... 2015 and will grow at a CAGR of 6.3% between ... the world and increasing functional requirements for healthcare packaging products ... healthcare packaging market. A global ageing population, changing ...
Breaking Biology Technology:U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 3Healthcare Packaging Market Forecast 2015-2025 2Healthcare Packaging Market Forecast 2015-2025 3Healthcare Packaging Market Forecast 2015-2025 4Healthcare Packaging Market Forecast 2015-2025 5Healthcare Packaging Market Forecast 2015-2025 6Healthcare Packaging Market Forecast 2015-2025 7Healthcare Packaging Market Forecast 2015-2025 8Healthcare Packaging Market Forecast 2015-2025 9Healthcare Packaging Market Forecast 2015-2025 10
... May 2011 - Optical data carriers such as DVDs, ... "phase change materials". In the future, these materials will ... memories. A prerequisite for this is a low thermal ... conductivity even in the crystalline state. This is described ...
... BELGRADE, Mont., May 3, 2011 Bacterin International Holdings, ... developer of revolutionary bone graft material, today announced that, ... in a private placement transaction.  The transaction was funded ... the date each tranche was submitted to NYSE Amex ...
... Reportlinker.com announces that a new market research report is ... Technologies and Global Markets http://www.reportlinker.com/p0488650/Medical-Enzymes-Technologies-and-Global-Markets.html ... medicine is growing. The global market for medical enzymes ... is growing at a compound annual growth rate (CAGR) ...
Cached Biology Technology:Nature of bonding determines thermal conductivity 2Nature of bonding determines thermal conductivity 3Bacterin International Secures $1.9 million in Private Placement 2Bacterin International Secures $1.9 million in Private Placement 3Reportlinker Adds Medical Enzymes: Technologies and Global Markets 2Reportlinker Adds Medical Enzymes: Technologies and Global Markets 3Reportlinker Adds Medical Enzymes: Technologies and Global Markets 4Reportlinker Adds Medical Enzymes: Technologies and Global Markets 5Reportlinker Adds Medical Enzymes: Technologies and Global Markets 6Reportlinker Adds Medical Enzymes: Technologies and Global Markets 7Reportlinker Adds Medical Enzymes: Technologies and Global Markets 8Reportlinker Adds Medical Enzymes: Technologies and Global Markets 9Reportlinker Adds Medical Enzymes: Technologies and Global Markets 10Reportlinker Adds Medical Enzymes: Technologies and Global Markets 11Reportlinker Adds Medical Enzymes: Technologies and Global Markets 12Reportlinker Adds Medical Enzymes: Technologies and Global Markets 13
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... collaborators have found, in a previously identified gene, a ... of isolated cleft lip. It is the first time ... alone, rather than both cleft lip and palate. ... mechanism and could eventually help with diagnosis, prevention and ...
... et al.report in the Journal of Cell Biology ... metastatic movement in tumor cells., On 2D surfaces, cells ... link the cell to the extracellular matrix, are known ... has been unclear. Recent work has suggested that an ...
... material could speed development of hydrogen powered vehicles , ... a new material that almost meets the U.S. Department of ... eliminate a key roadblock to practical hydrogen-powered vehicles. Their study ... is scheduled for the Oct. 8 issue of ACS, ...
Cached Biology News:Study finds genetic variant plays role in cleft lip 2Study finds genetic variant plays role in cleft lip 3American Chemical Society's Weekly PressPac 2American Chemical Society's Weekly PressPac 3American Chemical Society's Weekly PressPac 4American Chemical Society's Weekly PressPac 5American Chemical Society's Weekly PressPac 6American Chemical Society's Weekly PressPac 7American Chemical Society's Weekly PressPac 8
Human TSLP MAb (Clone 258136)...
HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems....
Human OSCAR MAb (Clone 259501)...
Human/Mouse G9a/EHMT2 MAb (Clone A8620A) Keywords: Eu-HMTase2...
Biology Products: